Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

• Published in: Cancer investigation Vol. 16; no. 2; p. 87
• Main Authors: Ritter, Jr, H L, Gralla, R J, Hall, S W, Wada, J K, Friedman, C, Hand, L, Fitts, D
• Format: Journal Article
• Language: English
• Published: England 1998
• Subjects: Adult; Aged; Aged, 80 and over; Antiemetics - administration & dosage; Antiemetics - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Cisplatin - adverse effects; Double-Blind Method; Drug Evaluation; Female; Granisetron - administration & dosage; Granisetron - adverse effects; Granisetron - therapeutic use; Humans; Injections, Intravenous; Male; Middle Aged; Nausea - chemically induced; Nausea - drug therapy; Vomiting - chemically induced; Vomiting - drug therapy
• DOI: 10.3109/07357909809039762
• ISSN: 0735-7907

The safety and efficacy of granisetron (10 micrograms/kg and 40 micrograms/kg) were evaluated during a second (n = 393) and third (n = 200) cycle of chemotherapy in this multicenter, double-blind, randomized, parallel-group study. Granisetron was administered as a single intravenous dose before the start of cisplatin chemotherapy (> or = 60 mg/m2). Total control (no vomiting, no retching, no nausea, and no use of antiemetic rescue medication) after the first 24 hr following chemotherapy was achieved in 40% and 49% of patients in Cycles 2 and 3, respectively, for the 10 micrograms/kg group, and in 42% and 38% of patients in Cycles 2 and 3, respectively, for the 40 micrograms/kg group. Both dose levels of granisetron were well tolerated. The results demonstrate comparable efficacy between the 10 micrograms/kg and 40 micrograms/kg doses of granisetron in preventing nausea and vomiting during repeat cycles of high-dose cisplatin-based chemotherapy. The results of this study show that granisetron 10 micrograms/kg is safe and well tolerated, and remains effective with repeat cycle use.